Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

  • Sideli, Lucia
  • Aas, Monica
  • Quattrone, Diego
  • La Barbera, Daniele
  • La Cascia, Caterina
  • Ferraro, Laura
  • Alameda, Luis
  • Velthorst, Eva
  • Trotta, Giulia
  • Tripoli, Giada
  • Schimmenti, Adriano
  • Fontana, Andrea
  • Gayer-Anderson, Charlotte
  • Stilo, Simona
  • Seminerio, Fabio
  • Sartorio, Crocettarachele
  • Marrazzo, Giovanna
  • Lasalvia, Antonio
  • Tosato, Sarah
  • Tarricone, Ilaria
  • Berardi, Domenico
  • D’Andrea, Giuseppe
  • EU-GEI WP2 Group
  • Arango, Celso
  • Arrojo, Manuel
  • Bernardo, Miguel
  • Bobes, Julio
  • Sanjuán, Julio
  • Santos, José Luis
  • Rossi Menezes, Paulo
  • Del-Ben, Cristina Marta
  • Jongsma, Hannah E.
  • Jones, Peter B.
  • Kirkbride, James B.
  • Llorca, Pierre-Michel
  • Tortelli, Andrea
  • Pignon, Baptiste
  • Haan, Lieuwe de
  • Selten, Jean-Paul
  • Os, Jim van
  • Rutten, Bart P. F.
  • Bentall, Richard
  • Di Forti, Marta
  • Murray, Robin M.
  • Morgan, Craig
  • Fisher, Helen L.
© The Author(s) 2023. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/., This study investigated if the association between childhood maltreatment and cognition among psychosis patients and community controls was partially accounted for by genetic liability for psychosis. Patients with first-episode psychosis (N = 755) and unaffected controls (N = 1219) from the EU-GEI study were assessed for childhood maltreatment, intelligence quotient (IQ), family history of psychosis (FH), and polygenic risk score for schizophrenia (SZ-PRS). Controlling for FH and SZ-PRS did not attenuate the association between childhood maltreatment and IQ in cases or controls. Findings suggest that these expressions of genetic liability cannot account for the lower levels of cognition found among adults maltreated in childhood., We are grateful to the EU-GEI study participants for their essential contribution to this project. The EU-GEI Study is funded by grant agreement HEALTH-F2-2010–241909 (Project EU-GEI) from the European Community’s Seventh Framework Programme, and Grant 2012/0417–0 from the São Paulo Research Foundation. B.P.F. Rutten is funded by a VIDI award (no. 91.718.336) from the Netherlands Scientific Organization. H. L. Fisher, C. Gayer-Anderson, and C. Morgan are supported by the Economic and Social Research Council (ESRC) Centre for Society and Mental Health at King’s College London [ES/S012567/1]. D. Quattrone is supported by the Medical Research Council Clinical Academic Research Partnership [MR/W030608/1]. M. Aas is supported by an MRC fellowship (#MR/WO27720/1). C. Arango has received support from the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union—NextGenerationEU (PMP21/00051, PI19/01024), CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (Project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. The views expressed are those of the authors and not necessarily those of the ESRC or King’s College London., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Exploring the Impact of Schizophrenia and Its Pharmacological Treatment on Health-Related Quality of Life and Treatment Preferences

  • Arango, Celso
  • Baeza, Inmaculada
  • García-Rizo, Clemente
  • Crespo-Facorro, Benedicto
  • Lahera, Guillermo
  • Vieta, Eduard
  • Becker, Frauke
  • Dwyer, Georges
  • Bourke, Siobhan
  • Gibson, Adam
  • Gabarda-Inat, Irene
  • Álvarez-Baron, Elena
The abstract of this paper was presented at the 36th ECNP Congress 2023 (Barcelona 7-10 October) as a poster presentation with interim findings. The poster’s abstract was published in Abstracts of the 36th ECNP Congress 2023 in Neuroscience applied (Vol2, Supplement 2): https://doi.org/10.1016/j.nsa.2023.103062., [Purpose:] Pharmacological treatments play an important role in managing symptoms of schizophrenia but can also be associated with side effects. The aim of this study was to understand the impact of schizophrenia and its pharmacological treatment on patients’ health-related quality of life (HRQoL) and to explore patient preferences around treatment benefits and side effects., [Patients and Methods:] This study employed a mixed methods approach with two stages of recruitment of adult patients in Spain. Stage 1 included qualitative and quantitative elements (including included two validated patient-reported outcome measures: PETiT and EQ-5D-5L) administered in telephone interviews with people with schizophrenia. Stage 2 consisted of a quantitative online survey completed by people with schizophrenia attending outpatient clinics. Responses to quantitative items across both stages were combined for analysis., [Results:] Twenty respondents completed the mixed methods interviews (stage 1), and 25 participants completed the online survey (stage 2). Results from stages 1 and 2, showed that participants perceived treatments to have a beneficial impact on controlling their symptoms. However, cognitive side effects were reported to have a detrimental impact on respondents’ daily life and were considered a primary reason for treatment cessation in the past. Qualitative findings further showed that most participants hoped future treatments would minimise the impact of cognitive symptoms of schizophrenia., [Conclusion:] The findings suggest that patients’ expectation around treatment efficacy and their acceptability of treatment side effects may indicate their capacity to maintain long-term treatment adherence. Trade-offs that patients may be willing to make between these components may prove useful to consider in clinical practice to improve treatment adherence and hence treatment effectiveness in people with schizophrenia., CA has been supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (ISCIII), co-financed by the European Union, ERDF Funds from the European Commission, “A way of making Europe”, financed by the European Union - NextGenerationEU (PMP21/00051), PI19/01024, PI22-01824.CIBERSAM, Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds, European Union Seventh Framework Program, European Union H2020 Program under the Innovative Medicines Initiative 2 Joint Undertaking: Project PRISM-2 (Grant agreement No.101034377), Project AIMS-2-TRIALS (Grant agreement No 777394), Horizon Europe, the National Institute of Mental Health of the National Institutes of Health under Award Number 1U01MH124639-01 (Project ProNET) and Award Number 5P50MH115846-03 (project FEP-CAUSAL), Fundación Familia Alonso, and Fundación Alicia Koplowitz. IB has been supported by the Spanish Ministry of Science and Innovation, Instituto de Salud Carlos III (PI21/0391), co-financed by the European Union, Drugs National Plan (2022I053) and Fundación Alicia Koplowitz., Peer reviewed